Epstein-Barr virus latent membrane protein 1-derived peptide–Major Histocompatibility Complex (EBV LMP1-pMHC)

Epstein-Barr virus latent membrane protein 1 (LMP1)-derived peptide–MHC complexes are specialized immunological targets consisting of processed fragments of the LMP1 oncoprotein presented on the cell surface by Major Histocompatibility Complex (MHC) molecules, most commonly HLA-A*02:01. LMP1 is a key driver of B-cell transformation and is constitutively expressed in various EBV-associated malignancies, including nasopharyngeal carcinoma and Hodgkin lymphoma. Because LMP1 is an intracellular or transmembrane protein with limited accessible extracellular domains, the presentation of its peptides (such as the immunodominant YLLEMLWRL) on MHC molecules provides a critical window for the immune system to identify and eliminate tumor cells. Therapeutic strategies targeting these complexes include T-cell receptor (TCR) engineered T-cells and TCR-like antibodies, which are designed to mimic the specificity of the natural immune response while bypassing the limitations of traditional monoclonal antibodies that require surface-bound whole proteins. These approaches are currently being explored in clinical and preclinical settings to treat EBV-positive cancers that are otherwise resistant to conventional therapies (Sources: PubMed PMID: 25713302, 30333305; UniProt P03230).

Other names

LMP1-HLA complexLMP1 peptide-MHC complexEBV LMP1-HLA-A*02:01 complexYLLEMLWRL-HLA-A2 complex

Targeting of the peptide-MHC complex by T-cell receptors (TCRs) or TCR-like antibodies to induce selective lysis of EBV-infected or malignant cells through granzyme/perforin secretion or antibody-dependent cellular cytotoxicity (ADCC).